Zobrazeno 1 - 10
of 172
pro vyhledávání: '"Michelle Maynard"'
Autor:
Jackie Sherrard, Rachel Pitt, Kate Russell Hobbs, Michelle Maynard, Eleanor Cochrane, Janet Wilson, Craig Tipple
Publikováno v:
International Journal of STD & AIDS. 33:740-750
The main objective of this guideline is to assist practitioners in managing individuals diagnosed with Trichomonas vaginalis (TV). It offers recommendations on the diagnostic tests, treatment regimens and health promotion principles needed for the ef
Autor:
Victoria Brown, Phil Ramsden, Nealia House, Richard Vargas, Jian Guo, Ruduan Wang, Riadh Lobbardi, Maxine Chen, Douglas Wilson, Joseph Kim, Neil Bifulco, Michelle Maynard, Emanuele Perola, Dean Zhang, Steve Wenglowsky, Yoon Jong Choi
Publikováno v:
Cancer Research. 82:2306-2306
Background: Cyclin-dependent kinases (CDK) are a class of enzymes that, along with their regulatory cyclin binding partners, drive cell cycle progression. Cell cycle dysregulation is a hallmark of cancer and targeting its genetic drivers can confer t
Autor:
Emily Rozsahegyi, Ruduan Wang, Riadh Lobbardi, Grace O. Silva, Joseph L. Kim, Dean Zhang, Victoria Tzortziou Brown, Jian Guo, Richard Vargas, Megan A. Hatlen, Marion Dorsch, Doug Wilson, Yoon Jin Choi, Rich Woessner, Phil Ramsden, Neil Bifulco, Michelle Maynard, Faith Stevison, Emanuele Perola, Rob Meissner, Klaus P. Hoeflich, Yeon Seo Choi, Tim LaBranche, Steve Wenglowsky
Publikováno v:
Cancer Research. 81:1279-1279
Background: Cyclin dependent kinases (CDK) comprise a family of proteins which are activated upon cyclin binding to promote cell cycle progression. Historically, CDK family inhibitors have had limited utility in the clinic due to 1) toxicities associ
Autor:
Elena Garralda, Joseph L. Kim, Michael Palmer, Wei Hu, Kevin J. Wilson, Michael Sheets, Douglas Wilson, Marcia S. Brose, Vivek Subbiah, Christoph Lengauer, Justin F. Gainor, Sai-Hong Ignatius Ou, Michelle Maynard, Beni B. Wolf, Paul Fleming, Erica Evans, Jason D. Brubaker, Matthew H. Taylor, Rami Rahal, Mimi I. Hu, Lori J. Wirth, Lucian DiPietro, Stephen D. Miller, Qiongfang Cao, Timothy Guzi
Publikováno v:
Cancer Discovery. 8:836-849
The receptor tyrosine kinase rearranged during transfection (RET) is an oncogenic driver activated in multiple cancers, including non–small cell lung cancer (NSCLC), medullary thyroid cancer (MTC), and papillary thyroid cancer. No approved therapie
Autor:
Vivek, Subbiah, Justin F, Gainor, Rami, Rahal, Jason D, Brubaker, Joseph L, Kim, Michelle, Maynard, Wei, Hu, Qiongfang, Cao, Michael P, Sheets, Douglas, Wilson, Kevin J, Wilson, Lucian, DiPietro, Paul, Fleming, Michael, Palmer, Mimi I, Hu, Lori, Wirth, Marcia S, Brose, Sai-Hong Ignatius, Ou, Matthew, Taylor, Elena, Garralda, Stephen, Miller, Beni, Wolf, Christoph, Lengauer, Timothy, Guzi, Erica K, Evans
Publikováno v:
Cancer discovery. 8(7)
The receptor tyrosine kinase rearranged during transfection (RET) is an oncogenic driver activated in multiple cancers, including non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC), and papillary thyroid cancer. No approved therapies
Autor:
Timothy J. Guzi, Jason D. Brubaker, Beni B. Wolf, Christoph Lengauer, Douglas Wilson, Timothy LaBranche, Michelle Maynard, Lucian Dipietro, Joseph L. Kim, Wei Hu, Kevin J. Wilson, Michael Sheets, Erica Evans, Qiangfang Cao, Rami Rahal
Publikováno v:
Clinical Cancer Research. 24:B01-B01
Activating RET fusions have been observed in 1-2% of non-small cell lung adenocarcinomas (NSCLC). These tumors often occur in non-smokers and lack other driver mutations, similar to NSCLC driven by activation of the tyrosine kinases EGFR, ALK or ROS.
Autor:
Joseph L. Kim, Douglas Wilson, Qiongfang Cao, Erica Evans, Paul E. Fleming, Timothy J. Guzi, Timothy LaBranche, Wei Hu, Kevin J. Wilson, Michael Sheets, Beni B. Wolf, Rami Rahal, Lucian Dipietro, Jason D. Brubaker, Michelle Maynard, Christoph Lengauer
Publikováno v:
Molecular Cancer Therapeutics. 17:B151-B151
Introduction: CCDC6-RET/PTC1 (papillary thyroid cancer gene 1) was one of the first gene fusions identified from a malignant epithelial tumor. Over the past 5 years, additional cancer types have been found to have oncogenic RET fusions, most notably
Publikováno v:
Antioxidants & Redox Signaling. 14:781-790
Postconditioning (PostC), or relief of myocardial ischemia in a stuttered manner, has been shown to reduce infarct size, due in part to upregulation of survival kinase signaling. Virtually all of these data have, however, been obtained in healthy adu
Publikováno v:
American Journal of Physiology-Heart and Circulatory Physiology. 291:H2008-H2012
Considerable attention has focused on the role of protein kinase C (PKC) in triggering the profound infarct-sparing effect of ischemic preconditioning (PC). In contrast, the involvement of inositol 1,4,5-trisphosphate [Ins( 1 , 4 , 5 )P3], the second
Autor:
Paul E. Fleming, Michael Sheets, Jason D. Brubaker, Lucian Dipietro, Erica Evans, Rami Rahal, Nicolas Stransky, Doug Wilson, Joseph L. Kim, Kevin J. Wilson, Wei Hu, Michelle Maynard, Nancy E. Kohl, Christoph Lengauer, Timothy J. Guzi
Publikováno v:
Cancer Research. 76:2641-2641
Introduction: RET/PTC1 was one of the first gene fusions identified from a solid tumor. In the past 3 years, oncogenic RET fusions have been identified in additional cancer types, most notably NSCLC and colon carcinomas. Activating germline RET mutat